The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | The factors associated with poor outcomes following CAR-T in patients with myeloma
Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, outlines the factors associated with poor outcomes following CAR T-cell therapy in patients with multiple myeloma (MM), the two most relevant being the presence of extramedullary disease and high tumor burden. Dr Tamariz-Amador highlights that, in this setting, classification using the Revised International Staging System (RISS) holds greater clinical utility than information on high-risk cytogenetics. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
